Enosi Life Sciences’ Sir Marc Feldmann to Join 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) — Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today that its co-founder and board member, Sir Marc Feldmann, will participate in the 2020 Tang Prize Masters’ Forum in Biopharmaceutical Science. The panel will take place on September 21 from 9:00pm-11:20pm EDT. It will be available through a live stream, broadcast in both English and Mandarin.

Due to his pioneering work which led to current widespread use of anti-TNF therapeutics, Sir Marc Feldmann shares the prize and the forum stage with Dr. Charles Dinarello and Dr. Tadamitsu Kishimoto, two renowned immunology researchers who identified Interleukin-1 Beta and Interleukin-6 cytokines, respectively. In addition to their use for inflammation and autoimmune diseases, biologics targeting these three cytokines are now being investigated as potential therapeutics for patients suffering from COVID-19. Some therapeutics are showing success in the treatment of abnormal cytokine responses, “cytokine storms” in these patients. Sir Marc Feldmann is one of the leaders of anti-TNF trials in the UK and US.

Sir Marc Feldmann and his colleagues identified the central role of TNF in inflammation, which triggered the development of anti-tumor necrosis factor (TNF) therapies for rheumatoid arthritis and other autoimmune and inflammatory diseases. With his colleague Sir Ravinder Maini, they used Remicade (Infliximab) to treat severe rheumatoid arthritis, not responding to other treatments. By working with Dr. Jim Woody at Centocor, now the Chairman of Enosi Life Sciences, Remicade was demonstrated to be the first anti-TNF therapeutic to show dramatic results for autoimmune diseases.

“Being a recipient of the 2020 Tang Prize is a great honor. There are only a few prestigious international awards for research in new therapeutics, with the Tang Prize among them, and I am very pleased to be recognized by my peers for my contributions,” said Sir Marc Feldmann, co-founder and board member of Enosi Life Sciences. “Importantly the Tang prize emphasizes the importance of the field of inflammatory mediators that my friends Charles Dinarello, Tadamitsu Kishimoto and I have spent our careers building.”

At Enosi Life Sciences, Sir Feldmann is working with co-founder Dr. Michael Shepard to create second generation, improved anti-TNF therapeutics, more precisely targeted for more effective treatment of inflammation, autoimmune diseases and cancer. Enosi currently has therapeutics in-development; EN1001, a TNFR1 binding protein that inhibits the pro-inflammatory TNFR1 without affecting the anti-inflammatory TNFR2’s healing capabilities, and EN2001, a multi-specific antibody receptor fusion protein that traps inflammatory growth factors and has been shown to complement anti-TNF drugs.

Sir Feldmann has shared his initial thoughts on being named a laureate, which can be found in a video shared by the association. To see Sir Feldmann’s presentation at the live-streamed 2020 Tang Prize awards program and Masters’ Forum, please visit the official Tang Prize website or follow its YouTube channel.

About Enosi Life Sciences
Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases ( Lasker Award, 2003); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins ( Lasker award, 2019). Enosi Life Sciences combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Life Sciences, visit www.enosi-life.com.

Company Contact
Ozan Pamir, CFO
Enosi Life Sciences
ozan@enositherapeutics.com
858-350-4392

IR Contact
Tom Becker
Enosi Life Sciences
investment@enositherapeutics.com
702-445-7038

Media Relations Contact
Kate Caruso-Sharpe
FischTank PR
enosi@fischtankpr.com
646-699-1534

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.